AHA Conference 2024 - Five-Year safety and efficacy follow-up outcomes investigating the non-inferiority of the AMPLATZER Amulet device (Abbott Medical Devices) against the commercially available WATCHMAN (Boston Scientific) device.

Dr Dhanunjaya Lakkireddy (University of Kansas Hospital, Kansas City, US) joins us onsite at AHA Conference to discuss the findings from Amulet IDE (NCT02879448).

Amulet IDE is a randomized, multi-center, active control, worldwide trial, were patients with non-valvular atrial fibrillation were randomized 1:1 to receive either the Amulet left atrial appendage (LAA) occlusion device or the WATCHMAN LAA closure device. 1,878 patients were randomized for the trial and were followed up at 45 days, 12 months and 18 months. The primary outcome measures were the composite endpoint rate of procedure-related complications or all-cause death or major bleeding, the composite rate of ischemic stroke or systemic embolism, and the rate of device closure.

Interview Questions:
1.    What is the importance behind the Amulet IDE trial?
2.    What was the study design and patient population?
3.    What were the key findings?
4.    What are the take-home messages for practice?
5.    What further research is needed in this area?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Arrhythmia Academy.